Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Upstream Processing in Biopharmaceuticals Introduction | 10 | 1 |
| GBI Research Report Guidance | 10 | 1 |
| Upstream Processing in Biopharmaceuticals -Biopharmaceuticals Overview | 11 | 9 |
| Important Classes of Biopharmaceuticals | 11 | 1 |
| Monoclonal Antibodies (mAb) | 12 | 1 |
| Vaccines | 12 | 1 |
| Hormones | 12 | 1 |
| Enzymes | 12 | 1 |
| Interferon | 12 | 1 |
| Clotting Factors | 12 | 1 |
| Therapeutic Protein | 13 | 1 |
| Biopharmaceutical Manufacturing Process Overview | 14 | 1 |
| Overview of Microbial Fermentation | 15 | 1 |
| Overview of Mammalian Cell Culture Systems | 15 | 1 |
| Cell Banking and Seed Culture | 15 | 1 |
| Research Cell Banks | 16 | 1 |
| Master Cell Banks | 16 | 1 |
| Working Cell Banks (WCB) | 16 | 1 |
| Overview of Upstream Process | 16 | 1 |
| Harvest | 17 | 1 |
| Downstream Process (DSP) | 17 | 1 |
| Initial Clarification | 18 | 1 |
| Initial Capture | 18 | 1 |
| Intermediate Purification | 18 | 1 |
| Final Polishing | 19 | 1 |
| Formulation | 19 | 1 |
| Comparison of Upstream Processing and Downstream Processing | 19 | 1 |
| Upstream Processing in Biopharmaceuticals Upstream Process In Detail | 20 | 10 |
| Introduction | 20 | 1 |
| Bioreactors and Cells | 21 | 2 |
| In Process Control | 23 | 1 |
| pH | 23 | 1 |
| Temperature | 24 | 1 |
| Effect of High Temperature | 24 | 1 |
| Effect of Low Temperature | 24 | 1 |
| Holding and Storage Time | 24 | 1 |
| Shear Forces | 24 | 1 |
| Key Points to be remembered while starting Up Upstream Processes | 24 | 1 |
| Major Issues during Upstream Processing | 25 | 1 |
| Scale Up | 25 | 1 |
| The Upstream Output can be increased | 26 | 1 |
| Use of Alternative Ways to Improve Protein Expression System | 26 | 1 |
| Disposable Technologies to Reduce the Process Time | 27 | 1 |
| Upstream Bioprocessing | 28 | 1 |
| Some Key Points While Starting Up Upstream Processes | 28 | 1 |
| Case Study: Use of Parallel Vessel Approach to Increase Productivity | 28 | 1 |
| Emerging Production Systems in Upstream Bioprocess | 29 | 1 |
| Efficient Filtration Mechanism | 29 | 1 |
| Contamination Detection Techniques | 29 | 1 |
| Conclusion | 29 | 1 |
| Upstream Processing in Biopharmaceuticals Market Characterization | 30 | 25 |
| Culture Media Overview | 30 | 1 |
| Cell Culture | 30 | 1 |
| Lysogeny Broth (LB) | 30 | 1 |
| Serum Free Media (SFM) | 30 | 1 |
| Protein-Free Media | 30 | 1 |
| Specialty Media | 31 | 1 |
| Key Biologic Reagents | 31 | 1 |
| Amino Acids | 31 | 1 |
| Growth Factors | 31 | 1 |
| Albumin | 31 | 1 |
| Transferrin | 31 | 1 |
| Culture Media/Reagent Suppliers | 32 | 1 |
| Culture Media/Reagent Market Size | 33 | 1 |
| Market Drivers | 34 | 1 |
| Huge Demand of Biologics and Regulatory Acceptance to Biosimilars will Drive Cell Culture Market | 34 | 1 |
| Development of Stem Cell Culturing Protocols and Technologies will Boost Cell Culture Market | 34 | 1 |
| Advancement in Biomedical Research | 35 | 1 |
| Vaccines Production by Using Cell Culture will be an Important Driver of the Market in the near Future | 35 | 1 |
| Market Restraints | 35 | 1 |
| Use of Transgenic Plants and Animals for the Biopharmaceutical Production is the Only Obstacle to the Cell Culture Market | 35 | 1 |
| Bioreactor | 35 | 1 |
| Selection of Bioreactors | 35 | 1 |
| Batch Bioreactor | 36 | 1 |
| Characteristics | 36 | 1 |
| Common Applications | 36 | 1 |
| Continuous Bioreactor | 37 | 1 |
| Key Features | 37 | 1 |
| Characteristics | 37 | 1 |
| Common Applications | 38 | 1 |
| Submerged Bioreactors Stirred Tank | 38 | 1 |
| Airlift Bioreactor | 38 | 1 |
| Characteristics | 38 | 1 |
| Summary | 38 | 1 |
| Upstream Process and CMO | 39 | 1 |
| Why CMO? | 39 | 1 |
| Build Vs. Buy Decision | 39 | 1 |
| Financial Considerations | 39 | 1 |
| Feasibility | 40 | 1 |
| Risk Management and Assessment | 40 | 1 |
| Strategic Fit | 40 | 1 |
| Conclusion | 40 | 1 |
| Selection of CMOs | 41 | 1 |
| Manufacturing Specialty | 41 | 1 |
| Scale of Manufacturing | 42 | 1 |
| Maintenance of Standard | 42 | 1 |
| Industry Reputation | 42 | 1 |
| CMO- Upstream Market Size | 43 | 1 |
| Drivers for Outsourcing | 44 | 1 |
| Manufacturing Cost Saving and Convenience in Various Biopharmaceutical Processes offered by CMO Encourages Outsourcing | 45 | 2 |
| Biotechnology Companies are Outsourcing to Reduce Operational Risk and Entry into the Market | 47 | 1 |
| Regulatory Changes | 47 | 1 |
| Growth in Biopharmaceuticals Market: Rise in Demand for Biologics Continues to Drive the Industry to Contract Manufacturing Services | 47 | 1 |
| Restraints to Outsourcing | 48 | 1 |
| Complex Cost Structures in Outsourcing | 48 | 1 |
| Time and Cost Associated with the Process of Outsourcing | 48 | 1 |
| Harmonization between In-house and Outsourced Process Makes Manufacturing More Difficult | 48 | 1 |
| Upstream Process Market Size | 49 | 1 |
| Upstream Process Trends | 50 | 1 |
| Inclination towards the Transgenic Plant/ Animals | 50 | 2 |
| R&D and Technology Based Advancements in Upstream Process | 52 | 1 |
| Focus on Single Use Technology | 52 | 1 |
| Upstream Process Drivers | 53 | 1 |
| Advances in Media and Cell-Line Development will Improve Overall Upstream Process Market | 53 | 1 |
| Innovations in Transgenic Production Systems will Drive Upstream Process Market in Future | 54 | 1 |
| Emergence of Newer Technologies Will Improve the Upstream Processing | 54 | 1 |
| Upstream Process Restraints | 54 | 1 |
| R&D Focus has Shifted to Downstream Process | 54 | 1 |
| High Cost and Time Spent in Upstream Process Affecting Productivity | 54 | 1 |
| Upstream Processing in Biopharmaceuticals Competitive Landscape | 55 | 18 |
| Key Players in the Culture Media and Reagents Market | 55 | 1 |
| Life Technologies | 55 | 1 |
| Company Overview | 55 | 1 |
| SWOT Analysis | 56 | 1 |
| Sigma Aldrich Corporation | 57 | 1 |
| Company Overview | 57 | 1 |
| SWOT Analysis | 58 | 1 |
| Millipore Corporation (a Merck KGaA company) | 59 | 1 |
| Company Overview | 59 | 1 |
| SWOT Analysis | 60 | 1 |
| Thermo Fisher Scientific | 61 | 1 |
| Company Overview | 61 | 1 |
| SWOT Analysis | 62 | 1 |
| Key CMO Players | 63 | 1 |
| Lonza Group Ltd (Lonza) | 63 | 1 |
| Company Overview | 63 | 1 |
| SWOT Analysis | 64 | 1 |
| Boehringer Ingelheim GmbH (Boehringer) | 65 | 1 |
| Company Overview | 65 | 1 |
| SWOT Analysis | 66 | 1 |
| Avecia Biotechnology | 67 | 1 |
| Company Overview | 67 | 1 |
| SWOT Analysis | 68 | 1 |
| Diosynth Biotechnology | 69 | 1 |
| Company Overview | 69 | 1 |
| SWOT Analysis | 70 | 1 |
| Sandoz GmbH (Sandoz) | 71 | 1 |
| Company Overview | 71 | 1 |
| SWOT Analysis | 72 | 1 |
| Upstream Processing in Biopharmaceuticals Technology Landscape | 73 | 15 |
| Transgenic Animals (A Live Bioreactor) | 73 | 1 |
| Transgenic Chickens | 74 | 1 |
| Proteins from Herd | 74 | 1 |
| Challenges | 74 | 1 |
| Transgenic Plants | 75 | 1 |
| Innovative Technologies | 76 | 1 |
| Lemna | 76 | 1 |
| Focus on Production of Oral Vaccines Edible Transgenic Plant | 77 | 1 |
| Plant Chloroplast Transformation | 78 | 1 |
| Challenges | 78 | 1 |
| Technical Challenges | 79 | 1 |
| Regulatory Challenges | 79 | 1 |
| Economic Challenges | 79 | 1 |
| Safety Concerns: Questions are being raised About Safety and Risk Associated with Transgenic Plants | 79 | 1 |
| Cell Culture | 80 | 1 |
| Innovative Technologies | 80 | 2 |
| Challenges | 82 | 1 |
| Single Use Disposable Bioreactors | 83 | 1 |
| Wave Reactor: (GE Healthcare) The maximum working volume for the Wave is 500 L | 83 | 1 |
| Single-Use Bioreactor (HyClone) available in sizes up to 1,000 L | 84 | 1 |
| Single-Use XDR Bioreactor (Xcellerex) | 84 | 1 |
| Hollow-Fiber Cartridges (Biovest) | 84 | 1 |
| Single-Use Mixing Systems | 84 | 1 |
| Some Recent Products Developed by Major Firms | 84 | 1 |
| Sartorius Stedim Biotech | 84 | 1 |
| Allegro | 84 | 1 |
| Wave Biotech | 84 | 1 |
| Millipore | 85 | 1 |
| Challenges | 85 | 1 |
| Low Rate of Implementation | 85 | 1 |
| Technology Improvement | 85 | 1 |
| Compatibility Challenge | 86 | 1 |
| Scale Up Challenge | 86 | 1 |
| Safety Issue | 86 | 1 |
| Use of Information Technology to Increase Productivity | 86 | 2 |
| Upstream Processing in Biopharmaceuticals Guidelines, Regulatory Landscape | 88 | 12 |
| Quality by Design (QbD) | 88 | 2 |
| Process Analytical Technology (PAT) | 90 | 1 |
| Importance of PAT | 91 | 1 |
| Factors Limiting Implementation of PAT | 91 | 1 |
| Real and Perceived Technological Barriers | 91 | 1 |
| Lack of Economic Incentive | 91 | 1 |
| A summary of PAT benefits is as follows: | 91 | 1 |
| ICH Guidelines | 92 | 1 |
| Q5A (R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin | 92 | 1 |
| Q5B: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products | 92 | 1 |
| Expression Construct and Cell Clone Used to Develop the Master Cell Bank (MCB) | 93 | 1 |
| Cell Bank System | 93 | 1 |
| Limit for In Vitro Cell Age for Production | 93 | 1 |
| Q5C: Quality of Biotechnological Products Stability Testing of Biological Products | 93 | 1 |
| Q5D: Derivation and Characterizations of Cell Substrates Used for Production of Biotechnological/Biological Products | 93 | 1 |
| Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process | 94 | 1 |
| The US Regulatory Landscape | 94 | 1 |
| PHS Act | 94 | 1 |
| Europe Regulatory Landscape | 95 | 1 |
| EMEA Guidelines | 95 | 1 |
| Quality Management | 95 | 1 |
| Production Activities | 96 | 1 |
| Buildings and Facilities | 96 | 1 |
| Process Equipment | 97 | 1 |
| Materials Management | 97 | 1 |
| Packaging and labeling | 97 | 1 |
| Key Changes in EMEA Guidelines | 98 | 1 |
| Types of Guidelines within the Biologics Legislative | 98 | 1 |
| Good Manufacturing Practice (GMP) Guidelines | 98 | 1 |
| Maximum Residue Limits Guidelines | 98 | 1 |
| Good Clinical Practice (GCP) and Conduct of Clinical Trial Guidelines | 98 | 1 |
| Good Distribution Practice (GDP) Guidelines | 98 | 1 |
| Japan | 98 | 1 |
| Health Policy Bureau | 98 | 1 |
| Office 1 | 99 | 1 |
| Office 2 | 99 | 1 |
| Review and Guidelines | 99 | 1 |
| Upstream Processing in Biopharmaceuticals Strategic Consolidations | 100 | 5 |
| Reasons for Strategic Consolidations in Biologics Manufacturing | 100 | 1 |
| Uninterrupted Supply to Meet the Demand | 100 | 1 |
| Overall Cost Reduction | 100 | 1 |
| Global Expansion to Stay Ahead in Competition | 100 | 1 |
| High Regulation Requirement | 100 | 1 |
| Acquiring Technical Expertise | 100 | 1 |
| Time Pressure and Synergy Innovation | 101 | 1 |
| Potential Problems in Strategic Consolidations | 101 | 1 |
| Incorrect Valuation | 101 | 1 |
| Capital Problem | 101 | 1 |
| Compliance Difficulty | 101 | 1 |
| Important Alliances in Biologics Manufacturing | 101 | 1 |
| Lonza in an Agreement with Odyssey Thera, Inc. | 101 | 1 |
| DSM Biologics (DSM) and Crucell NV Enter into an Agreement with Bioceros BV | 101 | 1 |
| Cobra Biomanufacturing Plc (Cobra) | 102 | 1 |
| Angel Biotechnology Holdings Plc | 102 | 1 |
| DSM Biologics Has Entered into an Agreement with Australian Governments to Build and Operate a Biopharmaceutical Manufacturing Facility in Brisbane | 102 | 1 |
| Lonza Enter into Licensing Agreement with Crucell | 102 | 1 |
| Gamida Cell Enters into Licensing Agreement with Amgen | 102 | 1 |
| Life Technologies Enters into Licensing Agreement with Indian Immunological | 103 | 1 |
| Recent M&A Deals in Biologics Manufacturing | 103 | 1 |
| Genmab Acquiring Manufacturing Facility Currently Owned By PDL Biopharma | 103 | 1 |
| BAYER Schering Pharma AG, Germany acquires a biologics manufacturing facility in from Novartis | 103 | 1 |